Monte Rosa Therapeutics, Inc. (GLUE) insider trading.
In Q3 2026, insiders at Monte Rosa Therapeutics, Inc. reported 11 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 5 sales worth $594K.
- Transactions
- 11
- Purchases (P)
- 0
- Sales (S)
- 5
- Net shares, P minus S
- -25,258
- Insiders
- 5
- Last filed
- 2026-07-17
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Townson Sharon | Officer · Chief Scientific Officer | 3 | 0 | 2 |
| Behbahani Ali | Director | 3 | 0 | 0 |
| Champoux Jennifer | Officer · Chief Operating Officer | 2 | 0 | 1 |
| Janku Filip | Officer · Chief Medical Officer | 2 | 0 | 1 |
| Warmuth Markus | Director, Officer · President & CEO | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Warmuth Markus | S (D) | 9,500 | $23.18 | 585,038 | Form 4 |
| 2026-07-15 | Champoux Jennifer | S (D) | 4,351 | $23.38 | 62,371 | Form 4 |
| 2026-07-15 | Champoux Jennifer | M (A) | 4,351 | $3.98 | 66,722 | Form 4 |
| 2026-07-06 | Townson Sharon | S (D) | 400 | $24.13 | 67,845 | Form 4 |
| 2026-07-06 | Townson Sharon | M (A) | 6,000 | $6.14 | 73,845 | Form 4 |
| 2026-07-06 | Townson Sharon | S (D) | 5,600 | $23.25 | 68,245 | Form 4 |
| 2026-07-01 | Behbahani Ali | J (D) | 15,000 | $0 | 0 | Form 4 |
| 2026-07-01 | Behbahani Ali | J (A) | 15,000 | $0 | 15,000 | Form 4 |
| 2026-07-01 | Behbahani Ali | J (D) | 1,000,000 | $0 | 6,692,298 | Form 4 |
| 2026-06-30 | Janku Filip | M (A) | 5,407 | $13.41 | 66,019 | Form 4 |
| 2026-06-30 | Janku Filip | S (D) | 5,407 | $24.5 | 60,612 | Form 4 |
Transaction codes in this quarter
Get GLUE insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1826457&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · GLUE company page · Monte Rosa Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Monte Rosa Therapeutics, Inc. (GLUE)?
In Q3 2026, insiders at Monte Rosa Therapeutics, Inc. reported 11 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 5 sales worth $594K. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Monte Rosa Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/glue.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.